Intellia Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Intellia Therapeutics' es John Leonard , nombrado en Jan 2018, tiene una permanencia de 6.25 años. compensación anual total es $10.10M, compuesta por 6.2% salario y 93.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.06% de las acciones de la empresa, por valor de $22.23M. La antigüedad media del equipo directivo y de la junta directiva es de 5.2 años y 9 años, respectivamente.

Información clave

John Leonard

Chief Executive Officer (CEO)

US$10.1m

Compensación total

Porcentaje del salario del CEO	6.2%
Permanencia del CEO	6.3yrs
Participación del CEO	0.9%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	9.1yrs

Actualizaciones recientes de la dirección

Recent updates

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Feb 09

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Feb 07

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Jan 01

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Oct 20

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep 01

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09

Intellia: Best All-Around Gene Editing Company

Jan 27

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Dec 15

Intellia Stock: Setting Up For Success

Nov 29

Intellia: A Step Closer To A Life-Changing Cure

Nov 21

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Oct 11

Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon

Aug 31

Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Aug 01

Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Jul 05

Intellia Makes History. Can It Deliver A Cure?

Jun 28

Intellia Therapeutics Q1 2021 Earnings Preview

May 05

Intellia Expands Its In Vivo Advantage

May 02

Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth

Apr 16

Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher

Mar 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Leonard en comparación con los beneficios de Intellia Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$481m
Sep 30 2023	n/a	n/a	-US$462m
Jun 30 2023	n/a	n/a	-US$453m
Mar 31 2023	n/a	n/a	-US$430m
Dec 31 2022	US$10m	US$630k	-US$474m
Sep 30 2022	n/a	n/a	-US$442m
Jun 30 2022	n/a	n/a	-US$400m
Mar 31 2022	n/a	n/a	-US$369m
Dec 31 2021	US$10m	US$600k	-US$268m
Sep 30 2021	n/a	n/a	-US$229m
Jun 30 2021	n/a	n/a	-US$185m
Mar 31 2021	n/a	n/a	-US$149m
Dec 31 2020	US$4m	US$580k	-US$134m
Sep 30 2020	n/a	n/a	-US$120m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$109m
Dec 31 2019	US$904k	US$559k	-US$100m
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$89m
Mar 31 2019	n/a	n/a	-US$86m
Dec 31 2018	US$10m	US$550k	-US$85m
Sep 30 2018	n/a	n/a	-US$90m
Jun 30 2018	n/a	n/a	-US$83m
Mar 31 2018	n/a	n/a	-US$76m
Dec 31 2017	US$3m	US$396k	-US$68m

Compensación vs. Mercado: La compensación total de John($USD10.10M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.57M).

Compensación vs. Ingresos: La compensación de John ha aumentado mientras la empresa no es rentable.

CEO

John Leonard (66 yo)

6.3yrs

Permanencia

US$10,096,590

Compensación

Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Leonard	President	6.3yrs	US$10.10m	0.86% $ 17.8m
Glenn Goddard	Executive VP	5.6yrs	US$3.43m	0.019% $ 385.7k
Laura Sepp-Lorenzino	Executive VP & Chief Scientific Officer	5yrs	US$3.72m	0.020% $ 414.4k
James Basta	Executive VP	2.9yrs	US$3.63m	0.018% $ 379.5k
David Lebwohl	Executive VP & Chief Medical Officer	4.1yrs	US$3.72m	0.030% $ 627.4k
Derek Hicks	Executive VP & Chief Business Officer	2.4yrs	US$5.08m	0.069% $ 1.4m
Nessan Bermingham	Founder & Member of Scientific Advisor Board	10yrs	US$11.27m	sin datos
Rachel Haurwitz	Co-Founder	10yrs	US$311.57k	sin datos
Andrew May	Founder and Member of Scientific Advisor Board	no data	sin datos	sin datos
Jennifer Doudna	Founder & Member of Scientific Advisor Board	no data	sin datos	sin datos
Derrick Rossi	Founder & Member of Scientific Advisor Board	no data	sin datos	sin datos
Rodolphe Barrangou	Founder & Member of Scientific Advisor Board	no data	sin datos	sin datos

5.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NTLA es experimentado (5.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Leonard	President	9.8yrs	US$10.10m	0.86% $ 17.8m
Nessan Bermingham	Founder & Member of Scientific Advisor Board	no data	US$11.27m	sin datos
Andrew May	Founder and Member of Scientific Advisor Board	no data	sin datos	sin datos
Jennifer Doudna	Founder & Member of Scientific Advisor Board	9.1yrs	sin datos	sin datos
Derrick Rossi	Founder & Member of Scientific Advisor Board	9.1yrs	sin datos	sin datos
Rodolphe Barrangou	Founder & Member of Scientific Advisor Board	no data	sin datos	sin datos
Luciano Marraffini	Founder & Member of Scientific Advisor Board	no data	sin datos	sin datos
Erik Sontheimer	Founder & Member of Scientific Advisor Board	no data	sin datos	sin datos
Arthur Krieg	Member of Scientific Advisory Board	no data	sin datos	sin datos
Beverly Davidson	Member of Scientific Advisory Board	9.3yrs	sin datos	sin datos
Franciscus A. G. Verwiel	Independent Chairman of the Board	6.8yrs	US$495.80k	0.0076% $ 156.0k
William Chase	Independent Director	1.1yrs	sin datos	0.0070% $ 145.5k

9.1yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de NTLA se considera experimentada (9 años de antigüedad promedio).

Intellia Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$566k worth of stock

Independent Director notifies of intention to sell stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Insufficient new directors

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Recent updates

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics Is On The Move

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Independent Director notifies of intention to sell stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings: EPS exceeds analyst expectations

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Price target decreased by 7.1% to US$96.27

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

Executive VP & Chief Scientific Officer notifies of intention to sell stock

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Consensus forecasts updated

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics down 12% following bottom line Q2 earnings miss

Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

Intellia Therapeutics: Several Catalysts Expected For H2 2022

Consensus forecasts updated

Price target decreased to US$137

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$155

Intellia: One Patent Ruling Turns The Industry Upside Down

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Consensus forecasts updated

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Intellia Therapeutics: A Lot Of News Can Bring The Stock Up

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia: Best All-Around Gene Editing Company

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Stock: Setting Up For Success

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Intellia: A Step Closer To A Life-Changing Cure